Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Zai Lab logo — Delivering innovative, transformational outcomes to patients...

Zai Lab

Delivering innovative, transformational outcomes to patients around the world

Founded 2014 China China 529 employees IPO Total: $2.59B Biotechnology, Health Care +1

General Information

Company Name Zai Lab
Founded Year 2014
Location China China
Employees 529
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage IPO
Business Model B2B, B2C, B2D
Revenue Model Product Sales, Licensing, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with Zai Lab. To contact Zai Lab, visit zailaboratory.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Zai Lab compare?

A PDF of Zai Lab and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Zai Lab soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Zai Lab

Zai Lab, founded in 2014, is a dynamic, commercial-stage biopharmaceutical company headquartered in China, with operations extending to the United States. The company's focus lies in the biotechnology, healthcare, and pharmaceutical industries, dedicated to discovering and bringing to market cutting-edge products that target critical medical needs in oncology, autoimmune disorders, infectious diseases, and neurological disorders.

Adhering to their slogan, "Delivering innovative, transformational outcomes to patients around the world," Zai Lab aims to impact global health positively, aspiring to reach one million patients by 2030. Their strategic capabilities promise transformative commercial outcomes, underpinned by a strong research and development ethos.

Their latest investment move was a Post IPO Debt round on 01 October 2025, secured from Industrial Bank. This indicates strong financial backing and investor confidence in their innovation-driven mission and potential for market growth.

Business keywords: biopharmaceuticals, oncology, autoimmune disorders, infectious diseases, neurological disorders, drug development, transformative medicines, global partnerships, clinical production, commercial production, regulatory environment, in-house manufacturing, pipeline expansion, biopharma commercialization, academic collaborations

Services & Products

Drug Discovery
Product Development
Manufacturing
Commercialization
Clinical Trials

Target Customers

Patients with Unmet Medical Needs Healthcare Providers Biopharmaceutical Partners

Funding Rounds & Investors (11)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Debt Undisclosed 1
Industrial Bank
01 Oct 2025
Post-IPO Equity $200.00M 1
Bank of Communications
01 Jan 2025
Private Placement VC $750.00M -
01 Apr 2021
IPO $761.00M -
01 Sep 2020
Post-IPO Equity $280.60M -
01 Jan 2020
Post-IPO Equity $215.40M -
01 May 2019
Post-IPO Equity $140.30M -
01 Sep 2018
Series C $115.00M -
01 Aug 2017
Series B $100.00M 5
Qiming Venture Partners OrbiMed AdvanTech Capital
Qiming Venture Partners, OrbiMed +3
01 Jan 2016
Series A Undisclosed 1
Qiming Venture Partners
Qiming Venture Partners
01 Apr 2015

View All 11 Funding Rounds

Zai Lab Alternatives & Competitors

View All Alternatives
Zai Lab vs
InnoCare Pharma
InnoCare Pharma China

Science drives innovation for the benefit of patients!

Post-IPO Equity
120 employees
Biotechnology, Health Care
Zai Lab vs
Odyssey Therapeutics
Odyssey Therapeutics

Building a machine learning-based platform to develop novel therapeutics focusing on cancer and auto...

IPO
127 employees
Biotechnology, Pharmaceutical
Zai Lab vs
Ultragenyx
Ultragenyx United States

Going Beyond Every Day

Post-IPO Equity
1535 employees
Biotechnology, Health Care
View all alternatives

FAQ About Zai Lab

Delivering innovative, transformational outcomes to patients around the world
Zai Lab was founded in 2014.
Zai Lab is headquartered in China.
Zai Lab operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on biopharmaceuticals, oncology, autoimmune disorders and infectious diseases. Its customers include Patients with Unmet Medical Needs, Healthcare Providers and Biopharmaceutical Partners.
Zai Lab has a B2B, B2C and B2D business model. Its revenue comes from Product Sales, Licensing and Service Fee.
Zai Lab has approximately 529 employees.
Zai Lab has completed 11 funding rounds, raising a total of $2.59B. The latest funding stage is IPO.
Zai Lab offers: Drug Discovery, Product Development, Manufacturing, Commercialization, Clinical Trials.
Top alternatives and competitors to Zai Lab include InnoCare Pharma, Odyssey Therapeutics, Ultragenyx, Moderna, Connect Biopharma. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Zai Lab and InnoCare Pharma are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Zai Lab, https://bouncewatch.com/company/zai-lab, updated 11 March 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes